Veru (VERU) to Release Quarterly Earnings on Thursday

Veru (NASDAQ:VERU) is expected to be releasing its Q2 2026 results before the market opens on Thursday, May 7th. Analysts expect Veru to post earnings of ($0.2850) per share and revenue of $1.90 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, May 14, 2026 at 8:00 AM ET.

Veru (NASDAQ:VERU) last released its quarterly earnings results on Wednesday, February 11th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.21. On average, analysts expect Veru to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Veru Trading Up 1.8%

VERU stock opened at $2.25 on Wednesday. Veru has a 12-month low of $2.06 and a 12-month high of $7.40. The business’s 50-day moving average is $2.39 and its 200 day moving average is $2.54. The stock has a market cap of $36.11 million, a price-to-earnings ratio of -1.79 and a beta of -1.19.

Analyst Upgrades and Downgrades

Several brokerages recently commented on VERU. Weiss Ratings reiterated a “sell (e+)” rating on shares of Veru in a research report on Monday, April 20th. Wall Street Zen cut shares of Veru from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Veru currently has an average rating of “Moderate Buy” and an average target price of $22.50.

Hedge Funds Weigh In On Veru

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Qube Research & Technologies Ltd purchased a new position in shares of Veru during the 2nd quarter worth $152,000. Blair William & Co. IL grew its holdings in shares of Veru by 26.3% in the fourth quarter. Blair William & Co. IL now owns 48,000 shares of the company’s stock valued at $103,000 after purchasing an additional 10,000 shares during the period. Bank of America Corp DE increased its position in Veru by 5.5% during the second quarter. Bank of America Corp DE now owns 185,669 shares of the company’s stock worth $108,000 after purchasing an additional 9,637 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Veru during the third quarter worth about $110,000. Finally, Osaic Holdings Inc. raised its stake in Veru by 11.9% during the second quarter. Osaic Holdings Inc. now owns 262,820 shares of the company’s stock worth $152,000 after purchasing an additional 27,954 shares during the period. Institutional investors and hedge funds own 47.16% of the company’s stock.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.